Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621000272897
Ethics application status
Approved
Date submitted
26/11/2020
Date registered
11/03/2021
Date last updated
11/03/2021
Date data sharing statement initially provided
11/03/2021
Date results provided
11/03/2021
Type of registration
Retrospectively registered

Titles & IDs
Public title
Can an intensive voice treatment reduce drooling in children with cerebral palsy (CP)?
Scientific title
The effects of the Lee Silverman Voice Treatment LOUD (LSVT LOUD®) on drooling and related outcomes for children with Cerebral Palsy (CP): A single case experimental design (SCED) method
Secondary ID [1] 302880 0
Nil known
Universal Trial Number (UTN)
U1111-1261-8856
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neurological 319878 0
Condition category
Condition code
Neurological 317815 317815 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
A behavioural intervention, an intensive voice treatment called the Lee Silverman Voice Treatment LOUD approach (LSVT LOUD®), will be implemented with a group of children (7 yrs to 18 yrs) with cerebral palsy. This is a single case experimental design and therefore each individual serves as their own control within the experiment. Each participant will be randomly assigned to one of three treatment conditions:
1. Baseline period of 10 days, treatment commencing day 11.
2. Baseline period of 14 days, treatment commencing day 15.
3. Baseline period of 18 days, treatment commencing day 19.
The content of the treatment delivered to each participant is the same. The duration of participation therefore differs across these three different treatment conditions. The behavioural target of LSVT LOUD® is loudness (of voice).The treatment involves a number of voice exercises that are practised in isolation and in functional contexts four times a week for four weeks (16 treatment sessions in total over the course of one month). Each treatment sessions lasts for 60-minutes and can be offered either online or face-to-face. The interventionist is a speech pathologist who is certified in delivering LSVT LOUD®. The exercises are: 15 repetitions of 'ah', 'high- pitched ah' and 'low-pitched ah'; 5 repetitions x 10 functional phrases (using newer louder voice e.g. What is for dinner?); reading words, sentences, paragraphs using newer louder voice; and there is 10-15 minutes of homework daily. The homework entails 6 repetitions only of the core exercises (loud ah/ high-pitched ah/ low-pitched ah); and a carryover assignment in which the participant uses their newer louder voice in a functional way e.g. speaking with a grandparent on the phone. A self-monitoring strategy will be used by the interventionist to monitor treatment fidelity in which a daily LSVT LOUD®) treatment protocol sheet will be filled out. Each treatment session will be audio-video recorded for fidelity checks. Primary outcomes to be evaluated: drooling severity and impact of drooling. Secondary outcomes: swallowing and speech intelligibility.
Intervention code [1] 319167 0
Treatment: Other
Intervention code [2] 319168 0
Behaviour
Comparator / control treatment
Each participant serves as their own control. The individual's own performance is compared between the baseline, intervention and follow up phases.
Control group
Active

Outcomes
Primary outcome [1] 325840 0
Drooling: 1) drooling severity (assessed using a validated outcome measure (Drooling Quotient, Van Hulst et al. 2011). No adverse effects from the intervention are known or anticipated.
Timepoint [1] 325840 0
5 timepoints in each of the three phases (baseline, intervention and follow up) in keeping with a concurrent multiple baseline single case experimental design.
Baseline: day 1 pre-intervention, day 3 pre-intervention, day 6 pre-intervention, day 10 pre-intervention, day 14 pre-intervention.
Treatment: day 1 post-intervention, day 3 post-intervention, day 6 post-intervention, day 10 post-intervention, day 14 post-intervention.
Follow up (3 months after treatment phase ends): day 91 post-intervention, day 94 post-intervention, day 97 post-intervention, day 101 post-intervention, day 105 post-intervention.
Primary outcome [2] 326132 0
2) impact of drooling (assessed using a validated parental completed questionnaire, the Drooling Impact Score (Reid et al, 2010).
Timepoint [2] 326132 0
1 timepoint in each of the three phases (baseline, intervention and follow up).
Baseline: day 5 pre-intervention.
Treatment: day 8 post-intervention,
Follow up (3 months after treatment phase ends): day 98 post-intervention,
Secondary outcome [1] 389285 0
Swallowing and feeding competency. The Dysphagia Disorders Survey (Sheppard, 2014) will be the validated scale used. This is an observational assessment of swallowing and feeding competency and will be completed by an independent trained assessor.
Timepoint [1] 389285 0
3 sets of data will be taken in each of the baseline, treatment and follow up phases for each participant.
Baseline: day 1 pre-intervention, day 6 pre-intervention, day 14 pre-intervention.
Treatment: day 1 post-intervention, day 6 post-intervention, day 14 post-intervention.
Follow up (3 months after treatment phase ends): day 91 post-intervention, day 97 post-intervention, day 105 post-intervention.
Secondary outcome [2] 390217 0
Speech intelligibility: The speech intelligibility sub-test of The Frenchay Dysarthria Assessment - 2nd edition (FDA-2) (Enderby, 2008), a validated assessment will be used.
Timepoint [2] 390217 0
3 sets of data will be taken in each of the baseline, treatment and follow up phases for each participant.
Baseline: day 1 pre-intervention, day 6 pre-intervention, day 14 pre-intervention.
Treatment: day 1 post-intervention, day 6 post-intervention, day 14 post-intervention.
Follow up (3 months after treatment phase ends): day 91 post-intervention, day 97 post-intervention, day 105 post-intervention.

Eligibility
Key inclusion criteria
(i) confirmed diagnosis of CP;
(ii) aged 7 to 18 years;
(iii) intelligence Quotient (IQ) at or above the moderate range of disability;
(iv) evidence of frequent and severe drooling, with a stable presentation over the previous 3 months;
(v) level I to III communicators on the Communication Function Classification System (CFCS) (Hidecker et al., 2011);
(vi) verbal communicators who were able to produce an ‘ah’ vocalisation;
(vii) sufficient language skills to produce at least 3-4 worded utterances;
(viii) overall speech intelligibility greater than 30% and/or no greater than ‘moderate to severe’ dysarthria;
(ix) demonstrated high compliance with previous speech pathology interventions (as pre-determined by parent and/or speech pathologist);
(x) ability to maintain independent head control; and
(xi) hearing within normal limits/ no dual diagnosis of hearing impairment.
Minimum age
7 Years
Maximum age
18 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria: (i) intellectual ability is greater than moderate-severe impairment (ii) presence of additional vocal pathology e.g. vocal nodules (iii) history of hoarse voice (iv) inconsistent drooling (periods when drooling is not present) (v) currently on medications that cause drooling e.g. clonazepam (vii) currently receiving other treatment for drooling e.g. block of oral sensory motor therapy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
* Allocation was concealed using sealed opaque envelopes.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
3. simple randomisation procedure
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
The research design is a single experimental design (SCED) and therefore each participant serves as 'their own control' within the experiment. The type of SCED is a concurrent multiple baseline SCED in which there are three phases, baseline, intervention and follow up phase.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
A systematic visual analysis (gold standard for data analysis when using SCEDs) will be completed, and supplemented with additional statistical techniques (Non overlap of all pairs(NAP)). Data on drooling (frequency and severity), swallowing and speech (word, sentence, conversational intelligibility) measures will be collected, entered into SPSS and plotted on graphic displays e.g., line graphs. A visual analysis includes the combined evaluation of level, trend, variability, immediacy of effect, data overlap in adjacent phases and consistency of data patterns in similar phases. Calculation of NAP will facilitate determining the size of treatment effect.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
8/11/2018
Date of last participant enrolment
Anticipated
Actual
23/01/2019
Date of last data collection
Anticipated
Actual
4/07/2019
Sample size
Target
6
Accrual to date
Final
5
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment postcode(s) [1] 32103 0
2060 - North Sydney

Funding & Sponsors
Funding source category [1] 307297 0
Government body
Name [1] 307297 0
National Health and Medical Research Council (NHMRC)
Country [1] 307297 0
Australia
Primary sponsor type
Other Collaborative groups
Name
Centre of Research Excellence Cerebral Palsy (CRE CP)
Address
Murdoch Children's Research Institute, Royal Children's Hospital, Flemington Rd., Parkville, VIC 3052, Australia.
Country
Australia
Secondary sponsor category [1] 307938 0
University
Name [1] 307938 0
Australian Catholic University
Address [1] 307938 0
Australian Catholic University, Level 3, Tenison Woods House, 8-20 Napier St, North Sydney, NSW 2060.
Country [1] 307938 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 307395 0
Australian Catholic University HREC
Ethics committee address [1] 307395 0
Ethics committee country [1] 307395 0
Australia
Date submitted for ethics approval [1] 307395 0
01/07/2018
Approval date [1] 307395 0
27/07/2018
Ethics approval number [1] 307395 0
2018-142H
Ethics committee name [2] 307397 0
Cerebral Palsy Alliance HREC
Ethics committee address [2] 307397 0
Ethics committee country [2] 307397 0
Australia
Date submitted for ethics approval [2] 307397 0
02/07/2018
Approval date [2] 307397 0
03/09/2020
Ethics approval number [2] 307397 0
2018_08_03.

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 107082 0
Dr Michelle McInerney
Address 107082 0
Australian Catholic University, Level 3, Tenison Woods House, 8-20 Napier St., North Sydney, NSW 2060.
Country 107082 0
Australia
Phone 107082 0
+61 2 94659118
Fax 107082 0
Email 107082 0
Michelle.McInerney@acu.edu.au
Contact person for public queries
Name 107083 0
Michelle McInerney
Address 107083 0
Australian Catholic University, Level 3, Tenison Woods House, 8-20 Napier St., North Sydney, NSW 2060.
Country 107083 0
Australia
Phone 107083 0
+61 2 94659118
Fax 107083 0
Email 107083 0
Michelle.McInerney@acu.edu.au
Contact person for scientific queries
Name 107084 0
Michelle McInerney
Address 107084 0
Australian Catholic University, Level 3, Tenison Woods House, 8-20 Napier St., North Sydney, NSW 2060.
Country 107084 0
Australia
Phone 107084 0
+61 2 94659118
Fax 107084 0
Email 107084 0
Michelle.McInerney@acu.edu.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Participant data underlying published data only (participants will be deidentified)
When will data be available (start and end dates)?
Immediately following publication, no end date.
Available to whom?
Case by case basis at the discretion of principal investigator/ lead researcher.
Available for what types of analyses?
Any purpose.
How or where can data be obtained?
Access subject to approval by principal investigator/ lead researcher. Contact details of principal investigator: Michelle.McInerney@acu.edu.au or +61 2 9465 9118.


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
9878Study protocol  Michelle.McInerney@acu.edu.au 381006-(Uploaded-29-01-2021-16-45-04)-Study-related document.pdf
9879Ethical approval    381006-(Uploaded-29-01-2021-16-48-06)-Study-related document.pdf



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.